Review




Structured Review

Agendia BV microarray-based clinical test mammaprint
Microarray Based Clinical Test Mammaprint, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+clinical+test+mammaprint/microarray+based+mammaprint/pm35565448-180-10-11
Average 90 stars, based on 1 article reviews
microarray-based clinical test mammaprint - by Bioz Stars, 2026-09
90/100 stars

Images

Related Articles

other:

Article Title: Modern Methods for Breast Cancer Diagnosis and Classification: A Current Update
Article Snippet: The incidence of cancer-related deaths worldwide has increased by 66% since 1960, according to the International Agency for Research on Cancer (IARC).. A breast cancer diagnosis is predicted to occur in one in eight women in the US alone at some point in their lifetime.. A BC diagnosis is typically made using high-end molecular bioimaging, ultrasound, and mammography.

Article Title: Prognostic Value of IGF2 mRNA-Binding Protein 3 (IGF2BP3) Intratumoral Expression in Melanoma Patients at the Time of Diagnosis: Comparative Analysis of RT-qPCR Versus Immunohistochemistry.
Article Snippet: Examples of these are the microarray-based clinical tests, such as MammaPrint (Agendia) [31] and ColoPrint (Agendia) [32] for breast and colon cancer recurrence risk prognosis, respectively, and the rising RNA seq-based tests, which are having significant prognostic and therapeutic relevance to cancer due to their capability of high reproducibility, accuracy, and precision [30,33,34].

Article Title: Tumour-Infiltrating Immune Cell-Based Subtyping and Signature Gene Analysis in Breast Cancer Based on Gene Expression Profiles
Article Snippet: Three multigene expression assays (PCR-based OncotypeDX (Genomic Health Inc., Redwood City, CA, USA) , , microarray-based MammaPrint (Agendia Inc., Amsterdam, Netherlands) , , NanoString-based PAM50 Prosigna Assay (NanoString Technologies Inc., Seattle, WA, USA) , ) have been used determine the risk of recurrence in patients with breast cancer.

Article Title: Prognostic Value of IGF2 mRNA-Binding Protein 3 (IGF2BP3) Intratumoral Expression in Melanoma Patients at the Time of Diagnosis: Comparative Analysis of RT-qPCR Versus Immunohistochemistry
Article Snippet: Examples of these are the microarray-based clinical tests, such as MammaPrint (Agendia) [ ] and ColoPrint (Agendia) [ ] for breast and colon cancer recurrence risk prognosis, respectively, and the rising RNA seq-based tests, which are having significant prognostic and therapeutic relevance to cancer due to their capability of high reproducibility, accuracy, and precision [ , , ].

Article Title: MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer.
Article Snippet: To be eligible for enrollment, patients with HR+/HER2− breast cancer also need to be at high risk for recurrence based on the MammaPrint (Agendia, Irvine, CA, USA) genomic test.

Article Title: Considering adjuvant therapy for stage II melanoma
Article Snippet: GEP testing for patients with breast cancer (Oncotype [Genomic Health Inc], MammaPrint [Agendia Inc]) is already well established and validated as an essential component to women with early stage breast cancer and defines treatment strategies, including the decision whether to offer adjuvant chemotherapy.

Microarray:

Article Title: Microarray and RNA in situ hybridization assay for recurrence risk markers of breast carcinoma and ductal carcinoma in situ : evidence supporting the use of diverse pathways panels
Article Snippet: .. Available predictive tests include the Agendia Mammoprint (microarray), Breast Cancer Index (qRT-PCR), EndoPredict (qRT-PCR), Oncotype DX (qRT-PCR), and Prosigna (NanoString technology) assays [ 1 – 5 ]. ..

Gene Expression:

Article Title: Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling
Article Snippet: .. In this scenario, personalized prediction tools such as gene expression profiling (eg, OncotypeDX [Genomic Health Inc., Redwood City, CA] or Mammaprint [Agendia Inc., Amsterdam, the Netherlands]) can calculate the likelihood of cancer recurrence and can help to risk stratify women who may not benefit from chemotherapy, sparing them from associated toxicity. ..



Similar Products

90
Agendia BV microarray-based clinical tests mammaprint
Microarray Based Clinical Tests Mammaprint, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+clinical+test+mammaprint/microarray+based+mammaprint/pmc09100051-273-10-11
Average 90 stars, based on 1 article reviews
microarray-based clinical tests mammaprint - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Agendia BV microarray-based clinical test mammaprint
Microarray Based Clinical Test Mammaprint, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+clinical+test+mammaprint/microarray+based+mammaprint/pm35565448-180-10-11
Average 90 stars, based on 1 article reviews
microarray-based clinical test mammaprint - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results